Nycomed To Sell Norgine Moviprep In Russia
Nycomed, a privately owned global pharmaceutical company with a strong presence in Europe and Russia, has entered into a licencing agreement with Norgine, gaining exclusive rights to market Norgine’s bowel-cleansing laxative Moviprep, the world’s leading bowel cleansing brand.
The deal covers Russia and the Commonwealth of Independent States (Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Mongolia, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan). No financial details were disclosed.
Moviprep is an osmotic laxative which can be used for any clinical procedure requiring a clean bowel, such as colonoscopy. Jostein Davidson, president of Nycomed Russia-CIS, noted that it has “proven to be the preferred choice for bowel preparation” in the European Union and the company will now work on getting approval in the aforementioned region.
Norgine’s chief executive Peter Stein commented that the deal is an important agreement for his company “as it will mark our entry into this fast developing market”. Moviprep is sold by Norgine and a number of other partners including Salix Pharmaceuticals (USA), Medical Futures (Canada) and PharmaSwiss (central and eastern Europe). It is under development with Ajinomoto in Japan.